There are currently 1881 clinical trials in Philadelphia, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pennsylvania, Children's Hospital of Philadelphia, Fox Chase Cancer Center and Thomas Jefferson University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
NCT04472338
Recruiting
This study investigates ways to detect prostate cancer earlier in people at genetic risk for disease that forms, grows, or spreads quickly (aggressive). Studying samples of blood, urine, and/or tissue in the laboratory may help doctors further understand the genetics of prostate cancer and help identify ways to detect cancer earlier, thereby improving treatment and methods of early detection in the future.
Gender:
MALE
Ages:
40 years and above
Trial Updated:
03/18/2025
Locations: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Conditions: Prostate Carcinoma
Register for Updates
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
NCT05602194
Recruiting
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often pr... Read More
Gender:
ALL
Ages:
Between 15 years and 40 years
Trial Updated:
03/18/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like
Register for Updates
Massage Impact on Sleep in Pediatric Oncology
NCT06892158
Recruiting
This study aims to determine the impact of massage therapy for pediatric patients receiving intensive chemotherapy or stem cell transplant (SCT).
Gender:
ALL
Ages:
Between 12 years and 21 years
Trial Updated:
03/18/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Cancer, Pediatric Cancer, Chemotherapy Effect, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Pediatric, Hematopoietic Stem Cell Transplantation (HSCT)
Register for Updates
CD22 Redirected Autologous T Cells for ALL
NCT02650414
Recruiting
This is a pilot study to determine the feasibility and safety of a single dose of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCR-ζ and 4-1BB signaling domains (CART22/CART22-65s cells) in pediatric and young adult subjects with relapsed or refractory B cell acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 1 year and 29 years
Trial Updated:
03/17/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: B Cell Leukemias, B Cell Lymphomas
Register for Updates
[18F] F-GLN by PET/CT in Breast Cancer
NCT03863457
Recruiting
Patients with known or suspected primary or metastatic breast cancer with one lesion that is 1.5 cm in diameter or greater may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 40 evaluable subjects will participate in a single imaging cohort. Patients will be stratified for analysis by breast cancer subtype with prioritization to recruit at least 10 estrogen-receptor-expressing (ER+) and 10 triple-negative breast cancers (TNBC). This... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Breast Cancer
Register for Updates
Medtronic Deep Brain Stimulation (DBS) Therapy for Epilepsy Post-Approval Study (EPAS)
NCT03900468
Recruiting
The purpose of this post-approval study is to further evaluate the long-term safety and effectiveness of Medtronic DBS therapy for epilepsy on seizure reduction in newly implanted participants through 3 years of follow-up.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Conditions: Epilepsy
Register for Updates
STRIVE Post-Market Registry Study
NCT04302272
Recruiting
This is a single-arm, prospective, multi-center, Registry study to evaluate the long-term safety and effectiveness of the Spiration Valve System (SVS) for the treatment of severe emphysema in a post-market setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Temple University, Philadelphia, Pennsylvania
Conditions: Emphysema
Register for Updates
Longitudinal Assessment of Traumatic Microvascular Injury-2
NCT05725993
Recruiting
The goal of this observational study is to learn about changes in the brain of patients over the first 3 years following a traumatic brain injury (TBI). The main question it aims to answer are: - How TBI effect the rate of brain tissue loss compare to healthy brain Participants will give blood samples, complete MRI scans, and neuropsychological assessment measures. Researchers will compare results between healthy control group and TBI group to determine changes in injured brains.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/17/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Traumatic Brain Injury
Register for Updates
Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation
NCT05917522
Recruiting
800 adult first time kidney transplant recipients will be enrolled in the Observational Study and followed to evaluate their Human Leukocyte Antigen (HLA)-DR/DQ molecular mismatch (mMM) score as a risk-stratifying prognostic biomarker. Six months after transplant the study will identify those who meet the eligibility criteria for the Nested Randomized Control Trial (RCT). 300 eligible subjects will be randomized 2:1 to abatacept or Standard of care (SOC) in the randomization and followed for 18... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/17/2025
Locations: University of Pennsylvania Medical Center: Transplantation, Philadelphia, Pennsylvania
Conditions: Kidney Transplant
Register for Updates
Trial to Increase FEP Attendance
NCT05967195
Recruiting
Individuals with first-episode psychosis (FEP) are at high-risk for several poor functional and clinical outcomes, including suicide. Coordinated Specialty Care (CSC) is a multidisciplinary, team-based intervention known to improve such outcomes, including suicide risk. However, 30-50% of patients disengage from CSC, thereby limiting its impact. This pilot study will develop and test feasibility of a behavioral change program that uses moderate financial incentives to encourage treatment engagem... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: PEACE Program, Horizon House, Inc., Philadelphia, Pennsylvania
Conditions: First-Episode Psychosis
Register for Updates
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
NCT04567550
Recruiting
ABBV-RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of Diabetic Retinopathy (DR) with and without Center-Involved Diabetic Macular Edema (CI-DME). DR is a chronic and progressive complication of diabetes mellitus. It is a sight-threatening disease characterized in the early stages by neuronal and vascular dysfunction in the retina, and later by neovascularization that leads to further deterioration of functional vision. Despite the availability... Read More
Gender:
ALL
Ages:
Between 25 years and 89 years
Trial Updated:
03/14/2025
Locations: Mid Atlantic Retina, Philadelphia, Pennsylvania
Conditions: Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
Register for Updates
The DISCOVER INOCA Prospective Multi-center Registry
NCT05288361
Recruiting
The overall objective of this multi-center registry is to identify specific phenotypes of INOCA with both an anatomic evaluation (coronary angiography and intravascular imaging) and physiologic assessment with the Abbott Coroventis Coroflow Cardiovascular System, and to determine long-term outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Conditions: Ischemia and no Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction, Coronary Vasospasm, Endothelial Dysfunction, Microvascular Angina, Chest Pain With Normal Coronary Angiography
Register for Updates